MedPath

PROFILE-MI - The FAPI Fibrosis Study

Completed
Conditions
Myocardial Infarction
Myocardial Fibrosis
Interventions
Radiation: 68Gallium FAPI PET/MR scan
Registration Number
NCT05356923
Lead Sponsor
University of Edinburgh
Brief Summary

The investigators here propose to investigate the timing and pattern of myocardial fibrosis activity following acute myocardial infarction using hybrid 68Ga-FAPI positron emission tomography and cardiovascular magnetic resonance. The investigators hypothesise that peak fibrosis activity will occur within 2-4 weeks of acute myocardial infarction and will predict subsequent scar formation and cardiac remodelling. Simultaneously, matrix remodelling and fibrosis activity in aortic and coronary atheroma will be assessed enabling the exploration of the presence of unstable atheroma.

Detailed Description

Fibrosis is a fundamental process underlying almost all cardiomyopathic conditions. Established fibrosis can be detected by existing imaging techniques including cardiovascular magnetic resonance. However, these techniques are not specific for fibrosis and do not directly measure fibrosis activity or matrix remodelling. This limits the ability to detect early disease and differentiate active from end-stage phenotypes. Fibroblast activation protein is a key factor in fibrogenesis that is expressed in the myocardium following myocardial infarction and in thin-capped fibroatheroma. Radiolabelled fibroblast activation protein inhibitor (68Ga-FAPI) measures in vivo fibrosis activity and matrix remodelling, as supported by preliminary pilot studies. The timing and pattern of myocardial fibrosis activity following acute myocardial infarction will be investigated using hybrid 68Ga-FAPI positron emission tomography. The investigators hypothesise that peak fibrosis activity will occur within 2-4 weeks of acute myocardial infarction and will predict subsequent scar formation and cardiac remodelling. Simultaneously, matrix remodelling and fibrosis activity in aortic and coronary atheroma will also be assessed allowing exploration of the presence of unstable atheroma. This project will enhance understanding of fibrosis activity and matrix remodelling in myocardial infarction and unstable atherosclerotic plaque with potential future application to a broad range of cardiovascular diseases.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • specific to cohort;
  • aged 50 years or older
Exclusion Criteria
  • Claustrophobia
  • Inability to undergo MRI
  • eGFR <30ml/min/1.73^m2

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Healthy volunteers68Gallium FAPI PET/MR scanAge- and sex- matched to participants, those aged 50 or over without known heart disease. n=20
Acute myocardial infarction - multi-timepoint imaging68Gallium FAPI PET/MR scanThose aged 50 or over with recent myocardial infarction who will be imaged using PET/MR at 1,2,4, and 12 weeks post-MI. n=20
Acute or chronic myocardial infarction - single timepoint imaging68Gallium FAPI PET/MR scanThose aged 50 or over with recent (n=20) or prior established (\>24 months, n=20) myocardial infarction who will be imaged at a single timepoint (1,2,4, or 12 weeks post-MI for acute, at the time of enrolement to the study for chronic).
Primary Outcome Measures
NameTimeMethod
Time of maximal fibrosis activity following myocardial infarction12 weeks

SUVmax and TBR of 68Ga-FAPI uptake within the infarct, border zone, and remote myocardium

Fibrosis activity and myocardial remodelling within atherosclerotic plaque in patients with myocardial infarct12 weeks

SUVmax and TBR of 68Ga-FAPI uptake within areas of atherosclerotic plaque in the aorta and/or carotid arteries

Whether fibrosis activity predicts myocardial scar volume and ventricular remodelling12 months

As measured by CMR 12 months following acute MI

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Royal Infirmary of Edinburgh

🇬🇧

Edinburgh, City Of Edinburgh, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath